Repro Med Systems (KRMD) Peer Comparison

$3.21

$0.01 (0.31%)

As on 28-Aug-2026 13:34EDT

Market cap

$147 Mln

Revenue (TTM)

$45 Mln

P/E Ratio

--

P/B Ratio

8.4

Div. Yield

0 %

Edit

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	147	12,753	10,906	10,222	9,762
Revenue ($ Mln)	45	1,505	613	785	2,589
Net Profit ($ Mln)	-1.82	160.59	-188.05	41.54	222.40
Net Margin (%)	-4.03	10.67	-30.68	5.29	8.59
RoE (%)	-10.37	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	8.36	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	45.11	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	17.15	483.98	127.96	384.30	1,245.50
Gross Profit	25.60	942.44	393.22	347.62	1,343.60
Operating Expenses	29.61	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-1.65	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-1.81	203.83	-192.83	52.15	350.40
Provision for Tax	0.01	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-1.82	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	18.05	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	2.73	210.18	135.71	705.49	2,116.80
Current Liabilities	7.18	233.78	102.33	132.66	961.30
Total Liabilities	28.20	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	8.45	630.60	404.74	1,749.63	7,231.50
Current Assets	19.51	1,344.12	515.78	1,200.55	3,020.50
Total Assets	28.20	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	3.24	212.71	102.84	690.94	1,203.70
Net Current Assets	12.33	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	0.46	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.95	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-0.22	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-12.76	11.76	-22.53	1.79	8.98
ROE (%)	-10.37	10.86	-28.10	1.97	3.04
ROA (%)	-5.45	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-4.01	13.63	-30.58	9.87	-5.99
Net Margin (%)	-4.03	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	22.41	17.55	41.55	16.49	1.37
EBIT Growth (%)	60.03	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	59.70	8.72	-102.66	400.42	-30.32
EPS Growth (%)	59.65	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	1.91	17.33	-12.65	2.16	2.19

Valuation Ratios

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-101.73	68.93	-34.59	189.42	--
Price / Book Value	15.74	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-145.65	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.03	0.01	0.00	0.01	0.06
Current Ratio	2.72	5.75	5.04	9.05	3.14
Quick Ratio	2.09	3.86	4.46	7.64	2.33
Interest Coverage	--	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Repro Med Systems (KRMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	13.51	12.65	22.67	20.09	17.06
Asset Turnover	1.35	0.74	0.59	0.26	0.24
Receivable days	55.63	46.54	60.95	72.41	65.39
Inventory Days	76.26	331.92	193.84	146.53	221.09
Payable days	46.09	26.16	60.19	29.05	37.02
Cash Conversion Cycle	85.80	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly